Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | CCR8 | P51685 | 4/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
| ▸ | ACP1 | P24666 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2925249 | 0.93 | MCHR1 (0.46) | MCHR1CCR8HTR1AADRA1DADRA1A | |
| SCHEMBL2930053 | 0.92 | MCHR1 (0.49) | MCHR1CCR8HTR1AADRA1DADRA1A | |
| SCHEMBL2930925 | 0.91 | HTR1A (0.42) | MCHR1CCR8HTR1AADRA1DADRA1A | |
| SCHEMBL2930915 | 0.85 | HRH3 (0.52) | — | |
| SCHEMBL2925293 | 0.84 | MCHR1 (0.49) | MCHR1CCR8HTR1AADRA1DADRA1A | |
| SCHEMBL2929111 | 0.84 | NCF1 (0.48) | MCHR1CCR8HTR1AADRA1DADRA1A | |
| SCHEMBL2929685 | 0.77 | APP (0.56) | — | |
| SCHEMBL2928104 | 0.77 | APP (0.51) | — | |
| SCHEMBL18499175 | 0.76 | HRH3 (0.44) | — | |
| SCHEMBL2928148 | 0.75 | APP (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121616-B1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | CAMPIANI GIUSEPPE (IT) | 2010-09-15 | — | — | EP | claimed |
| US-20100093726-A1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | GIUSEPPE CAMPIANI (IT) | 2010-04-15 | — | — | US | claimed |
| EP-2121616-B1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | CAMPIANI GIUSEPPE (IT) | 2010-09-15 | — | — | EP | disclosed |
| US-20100093726-A1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | GIUSEPPE CAMPIANI (IT) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093726-A1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | QTRT1, QTRT2, IL4I1 | MCHR1 3775/4885CCR8 4326/4885HTR1A 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.